Intuitive Surgical (NASDAQ:ISRG) Price Target Raised to $575.00

Intuitive Surgical (NASDAQ:ISRG) had its target price raised by analysts at Jefferies Financial Group from $475.00 to $575.00 in a research report issued on Monday. Jefferies Financial Group’s target price would indicate a potential upside of 0.15% from the stock’s previous close.

Several other equities analysts also recently commented on the stock. Erste Group Bank upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Tuesday, November 19th. Citigroup increased their price target on Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a report on Friday, January 24th. BTIG Research raised their price target on Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. The Goldman Sachs Group set a $604.00 price objective on Intuitive Surgical in a research report on Friday, October 18th. Finally, Stifel Nicolaus lifted their target price on Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. One analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average target price of $613.10.

Intuitive Surgical Stock Up 0.1 %

NASDAQ ISRG opened at $574.14 on Monday. Intuitive Surgical has a 52 week low of $364.17 and a 52 week high of $616.00. The firm has a market capitalization of $204.50 billion, a price-to-earnings ratio of 92.31, a PEG ratio of 5.19 and a beta of 1.39. The company has a fifty day moving average of $548.00 and a two-hundred day moving average of $506.12.

Insider Transactions at Intuitive Surgical

In other news, insider Jamie Samath sold 269 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $539.89, for a total transaction of $145,230.41. Following the transaction, the insider now directly owns 8,757 shares of the company’s stock, valued at approximately $4,727,816.73. This represents a 2.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Amal M. Johnson sold 4,635 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the sale, the director now directly owns 12,275 shares of the company’s stock, valued at $6,955,015. The trade was a 27.41 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 28,749 shares of company stock valued at $15,303,875. Corporate insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ISRG. Berbice Capital Management LLC acquired a new stake in Intuitive Surgical in the 4th quarter worth approximately $26,000. Godsey & Gibb Inc. lifted its stake in shares of Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 35 shares during the period. MidAtlantic Capital Management Inc. acquired a new position in shares of Intuitive Surgical in the 3rd quarter valued at $33,000. Decker Retirement Planning Inc. purchased a new position in Intuitive Surgical in the 4th quarter worth $36,000. Finally, Capital Performance Advisors LLP acquired a new stake in Intuitive Surgical during the 3rd quarter worth about $38,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.